7h agoStocktwits NewsBULLISH 63Product/PR
AXSM Stock Advances on CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030
The FDA has already accepted the company’s application seeking the greenlight for AXS-12.
Why Is AXSOME THERAPEUTICS (AXSM) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 9 wire stories
AXSOME THERAPEUTICS (AXSM) is drawing unusual attention today. Our newswire has captured 9 stories on AXSM across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for AXSM publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
AXSM by the numbers
Coverage: 9 stories / 7 sourcesAI sentiment: 58/100 (bullish)
The headlines behind the move
9h agoSeeking AlphaBULLISH 67Product/PR
Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA
Axsome (AXSM) Q2 2026 earnings call: $218M revenue (+46% YoY), AUVELITY Alzheimer’s agitation launch, pipeline & cash runway insights—read now.
9h agoSeeking AlphaNEUTRAL 50Earnings
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call August 10, 2026 8:00 AM EDTCompany ParticipantsAshley DongHerriot Tabuteau - Founder, Chairman, CEO...
11h agoInvestorsHubBULLISH 56Earnings
Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss
Axsome Therapeutics shares rise 2% despite a Q2 earnings miss as revenue grows 46%, AUVELITY sales jump 51% and its Alzheimer’s agitation launch gains momentum.
14h agoMarketChameleonBULLISH 73Earnings
Axsome’s 46% Revenue Surge Underscores Expanding CNS Franchise and Pipeline Momentum August 10, 2026
Axsome Therapeutics reported a robust 46% year-over-year revenue increase in Q2 2026, driven by rising demand for its CNS drugs—especially AUVELITY’s strong debut in the Alzheimer’s agitation market. Despite an expanded commercial footprint and R&D pipeline, the company maintained solid fundamentals and anticipates further milestone catalysts ahead.
14h agoThe FlyBULLISH 68Earnings
Axsome Therapeutics Reports Q2 Eps 99c Consensus 85c
15h agoSEC 8-KNEUTRAL 50General
Axsome Therapeutics, Inc. (AXSM) files 8-K
Filed: 2026-08-10 AccNo: 0001193125-26-341206 Size: 18 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
15h agoSeeking AlphaBEARISH 34Earnings
Axsome Therapeutics GAAP EPS of -$0.99 misses by $0.10, revenue of $218.4M misses by $3.38M
If you type a company or ETF ticker symbol in capital letters we will automatically link to the symbol page. You can remove the link by deleting the $ in the comment.
15h agoBusiness InsiderBULLISH 59Earnings
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year...
Frequently asked questions
Why is AXSM stock moving today?
AXSOME THERAPEUTICS (AXSM) is drawing unusual attention today. Our newswire has captured 9 stories on AXSM across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100). The most recent driver: "AXSM Stock Advances on CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030" (Stocktwits News).
Is AXSM a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of AXSM coverage reads 58/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is ABCL up today (+34.78%)
- Why is OBX up today (+27.27%)
- Why is NESR up today (+23.33%)
- Why is FSLY up today (+20.86%)
- Why is BTDR down today (-20.08%)
- Why is BSP up today (+15.70%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AXSM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.